Anti-IL-23 antibodies, compositions, methods and uses
An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
1. An isolated nucleic acid molecule encoding an IL-23p19 antibody capable of binding to human IL-23p19 at one or more regions of human IL-23p19 consisting of the amino acid residues selected from the group consisting of residues 93-102, 93-110, and 127-137 of SEQ ID NO:1.
2. An isolated nucleic acid vector comprising the isolated nucleic acid molecule of claim 1 .
3. An isolated host cell comprising the isolated nucleic acid molecule of claim 1 , wherein the host cell is prokaryotic or eukaryotic.
4. The isolated host cell of claim 3 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, and lymphoma cells.
5. A method for producing an IL-23p19 antibody, culturing the isolated host cell of claim 4 under conditions such that the IL-23p19 antibody is expressed and recovered.
6. The isolated nucleic acid of claim 1 , wherein said antibody is selected from the group consisting of rodent, chimeric, humanized, and human.
7. An isolated nucleic acid molecule encoding an IL-23p19 antibody that competitively binds to IL-23p19 with the isolated IL-23p19 antibody encoded by the nucleic acid molecule of claim 1 .
8. An isolated nucleic acid molecule encoding an IL-23p19 antibody, comprising at least one light chain variable region and at least one heavy chain variable region, said light chain variable region nucleotide sequence comprising:
(a) a complementarity determining region light chain 1 (CDRL1) nucleotide sequence encoding the amino acid sequence of SEQ ID NO:9;
(b) a CDRL2 nucleotide sequence encoding the amino acid sequence of SEQ ID NO:10; and
(c) a CDRL3 nucleotide sequence encoding the amino acid sequence of SEQ ID NO:11,
and said heavy chain variable region nucleotide sequence comprising:
(d) a complementarity determining region heavy chain 1 (CDRH1) nucleotide sequence encoding the amino acid sequence of SEQ ID NO:4;
(e) a CDRH2 nucleotide sequence encoding the amino acid sequence of SEQ ID NO:5; and
(f) a CDRH3 nucleotide sequence encoding the amino acid sequence of SEQ ID NO:6.
9. The isolated nucleic acid molecule of claim 8 , comprising a nucleotide sequence encoding the light chain variable region amino acid sequence of SEQ ID NO:8.
10. The isolated nucleic acid molecule of claim 8 , comprising a nucleotide sequence encoding the heavy chain variable region amino acid sequence of SEQ ID NO:3.
11. An isolated nucleic acid molecule, comprising the nucleotide sequence of claim 9 and a nucleotide sequence encoding the heavy chain variable amino acid sequence of SEQ ID NO:3.
12. An isolated nucleic acid molecule encoding an IL-23p19 antibody that competitively binds to IL-23p19 with the isolated IL-23p19 antibody encoded by the nucleic acid molecule of claim 11 .